169 related articles for article (PubMed ID: 31776936)
1. Place of Academic GMP Facilities in Modern Cell Therapy.
Bersenev A; Fesnak A
Methods Mol Biol; 2020; 2097():329-339. PubMed ID: 31776936
[TBL] [Abstract][Full Text] [Related]
2. Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting.
Iancu EM; Kandalaft LE
Curr Opin Biotechnol; 2020 Oct; 65():233-241. PubMed ID: 32663771
[TBL] [Abstract][Full Text] [Related]
3. Regulation of advanced therapy medicinal products in Europe and the role of academia.
Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
[TBL] [Abstract][Full Text] [Related]
4. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
Sutherland V; Buffo MJ; Whiteside TL
Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility.
Digiusto DL; Melsop K; Srivastava R; Tran CT
Cytotherapy; 2018 Dec; 20(12):1486-1494. PubMed ID: 30377039
[TBL] [Abstract][Full Text] [Related]
6. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
[TBL] [Abstract][Full Text] [Related]
7. Challenges of translating a cell therapy to GMP.
Bauer G; Fury B
Int Rev Neurobiol; 2022; 166():207-234. PubMed ID: 36424093
[TBL] [Abstract][Full Text] [Related]
8. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P
Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061
[TBL] [Abstract][Full Text] [Related]
9. Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit.
Johanna I; Daudeij A; Devina F; Nijenhuis C; Nuijen B; Romberg B; de Haar C; Haanen J; Dolstra H; Bremer E; Sebestyen Z; Straetemans T; Jedema I; Kuball J
Immunooncol Technol; 2023 Dec; 20():100411. PubMed ID: 38192616
[TBL] [Abstract][Full Text] [Related]
10. Cell and gene therapy manufacturing capabilities in Australia and New Zealand.
O'Sullivan GM; Velickovic ZM; Keir MW; Macpherson JL; Rasko JEJ
Cytotherapy; 2019 Dec; 21(12):1258-1273. PubMed ID: 31806531
[TBL] [Abstract][Full Text] [Related]
11. Translating cell-based regenerative medicines from research to successful products: challenges and solutions.
Bayon Y; Vertès AA; Ronfard V; Egloff M; Snykers S; Salinas GF; Thomas R; Girling A; Lilford R; Clermont G; Kemp P
Tissue Eng Part B Rev; 2014 Aug; 20(4):246-56. PubMed ID: 24754565
[TBL] [Abstract][Full Text] [Related]
12. Topical delivery of cultured stem cells to human non-healing wounds: GMP facility development in an academic setting and FDA requirements for an IND and human testing.
Yufit T; Carson P; Falanga V
Curr Drug Deliv; 2014; 11(5):572-81. PubMed ID: 23517627
[TBL] [Abstract][Full Text] [Related]
13. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell therapy manufacturing: process development technologies and facility design options.
Abbasalizadeh S; Pakzad M; Cabral JMS; Baharvand H
Expert Opin Biol Ther; 2017 Oct; 17(10):1201-1219. PubMed ID: 28699788
[TBL] [Abstract][Full Text] [Related]
15. Cellular manufacturing for clinical applications.
Sheu J; Klassen H; Bauer G
Dev Ophthalmol; 2014; 53():178-88. PubMed ID: 24732771
[TBL] [Abstract][Full Text] [Related]
16. National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells.
Elsallab M; Bourgeois F; Maus MV
Transplant Cell Ther; 2024 Jun; 30(6):626.e1-626.e11. PubMed ID: 38494077
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II Manufacture of Lentiviral Vectors Under GMP in an Academic Setting.
Dasgupta A; Tinch S; Szczur K; Ernst R; Shryock N; Kaylor C; Lewis K; Day E; Truong T; Swaney W
Methods Mol Biol; 2020; 2086():27-60. PubMed ID: 31707666
[TBL] [Abstract][Full Text] [Related]
18. Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers.
Phinney DG; Galipeau J;
Cytotherapy; 2019 Jul; 21(7):782-792. PubMed ID: 31182333
[TBL] [Abstract][Full Text] [Related]
19. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
[TBL] [Abstract][Full Text] [Related]
20. Topical otic drugs in a multi-purpose manufacturing facility: a guide on determination and application of permitted daily exposure (PDE).
Wiesner L; Prause M; Lovsin Barle E
Pharm Dev Technol; 2018 Mar; 23(3):261-264. PubMed ID: 28535123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
